2 news items
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia
LRMR
20 May 24
ability and the ability of third-party manufacturers Larimar engages, to optimize and scale nomlabofusp's manufacturing process; Larimar's ability
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
LRMR
9 May 24
manufacturers Larimar engages, to optimize and scale nomlabofusp's manufacturing process; Larimar's ability to obtain regulatory approvals
- Prev
- 1
- Next